Evidence map›Paper›PMID 37148318›Full record

ArticleArchives of toxicology2023

Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities.

Joost Boeckmans, Alexandra Gatzios, Jörn M Schattenberg, Robim M Rodrigues, Vera Rogiers, Tamara Vanhaecke

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joost BoeckmansIn Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. Joost.Boeckmans@vub.be.ORCID http://orcid.org/0000-0001-8399-5872
Alexandra GatziosIn Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID http://orcid.org/0000-0001-7478-3405
Jörn M SchattenbergMetabolic Liver Research Center, Department of Medicine, University Medical Center Mainz, Mainz, Germany.ORCID http://orcid.org/0000-0002-4224-4703
Robim M RodriguesIn Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID http://orcid.org/0000-0003-2927-6791
Vera RogiersIn Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID http://orcid.org/0000-0003-0635-7740
Tamara VanhaeckeIn Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID http://orcid.org/0000-0002-6685-7299

Funding

Research Foundation Flanders 1S91923N
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Non-alcoholic Fatty Liver DiseasePharmacogeneticsHumans

Identifiers

PMID37148318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.